Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
Pavlick A, Ariyan C, Buchbinder E, Davar D, Gibney G, Hamid O, Hieken T, Izar B, Johnson D, Kulkarni R, Luke J, Mitchell T, Mooradian M, Rubin K, Salama A, Shirai K, Taube J, Tawbi H, Tolley J, Valdueza C, Weiss S, Wong M, Sullivan R. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0. Journal For ImmunoTherapy Of Cancer 2023, 11: e006947. PMID: 37852736, PMCID: PMC10603365, DOI: 10.1136/jitc-2023-006947.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsClinical practice guidelinesCutaneous melanomaTreatment of melanomaPractice guidelinesProlongs recurrence-free survivalCancer clinical practice guidelinesCell death protein 1Metastatic cutaneous melanomaBispecific T cell engager (BiTE) therapyChemotherapy-resistant diseaseRecurrence-free survivalDeath protein 1Long-term followManagement of patientsSpecial patient populationsImmunotherapy of cancerConsensus-based recommendationsPossibility of cureUnique toxicity profileQuality of lifeIntratumoral immunotherapyNeoadjuvant strategiesAdvanced diseaseBrain metastases